After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and winter — even as a new Trump administration policy has thrown into question ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

19日の米株式市場で米バイオテクノロジー企業ノババックスの株価が急伸した。米規制当局が同社の新型コロナウイルスワクチンを完全に承認したことで、承認遅延や有効性を疑問視するケネディ厚生長官の発言により高まっていた市場の不安が和らいだ。

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and ...

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are ...